tbuckley/cabot-search huggingface dataset:
SAT0222 Clinical risk stratification for hydroxychloroquine prescribing in a large urban district general hospital
Authors: A. Saravanan, T. Ahmed
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background:</h3> New 2017 British Society of Rheumatology guidelines have recommended baseline formal ophthalmic examination, ideally including objective retinal assessment for example using optical coherence tomography, within 1 year of commencing an antimalarial drug. While the feasibility and costing of this recommendation is being assessed, we audited the current risk assessment for hydroxychloroquine prescriptions (HCQ) against the American College of Ophthalmology (ACO) guidelines for HCQ published in 2016. Table 1 shows the clinical criteria for assessment. <h3>Methods:</h3> We identified all prescriptions of HCQ documented on the electronic patient records (EPR) from January to September 2017 by the Rheumatology department of Croydon University Hospital. This generated 237 records of which 114 were new prescriptions and 117 were continuation prescriptions. 8 records were excluded due to inadequate patient compliance. Cumulative doses were estimated from dates in the EPR going back to 2013 <h3>Results:</h3> New patient records were assessed for compliance with the ACO guidelines. Patients were assessed for kidney function, pre-existing renal disease, pre- existing eye disease. 74.6% patients were counselled regarding side effects and were advised to have optician retinal screening and 3.5% who had pre-existing eye disease were referred to ophthalmologists. 50.0% of patients had their weight documented prior to prescription. There was no documentation of dose calculated by weight. The commonest indication for HCQ were Systemic Lupus Erythmatosis, Inflammatory Arthritis and Sjogren's Syndrome. 13.2 % discontinued HCQ due to side effects. The commonest side effects were diarrhoea, dizziness, rashes, and mood swings. Long- term patient records were assessed for cumulative dose of HCQ estimated from documentation. The average cumulative dose for these patients was with a maximum of 810,000 mg and a minimum of 49,600 mg. Overall, 3.0% percentage of patients did not have cumulative doses calculated due to documented compliance issues and 64.0% of patients had tightly monitored renal function. <h3>Conclusions:</h3> 50% of patients had weight documented prior to prescription and this was not used to determine dosage. The majority of patients were well informed regarding side-effects of HCQ, had tightly monitored renal function and advised to have baseline retinal screening. <h3>Disclosure of Interest:</h3> None declared
Neville Keith Shinton
Authors: Roger Shinton
Journal: BMJ (2019)

From the 1950s onwards Neville Keith Shinton was at the heart of the rapidly developing specialty of clinical haematology in the West Midlands and beyond. His diligence and firm but polite approach ensured that he was recruited to support many initiatives. Locally he chaired the regional haematology training committee and was a member of the regional hospital board, chairman of the regional research committee, regional adviser to the Royal College of Physicians, chairman of the Coventry British Medical Association, and professor of postgraduate medical education at the University of Warwick. Nationally Keith worked for the British Standards Institute and the British National Formulary before being elected to the council of the Royal College of Pathologists as well as becoming president of the Association of Clinical Pathologists, and treasurer and then president of the British Society for …
Abstract 16066: Automated External Defibrillators Are Widely Distributed in Danish Hospitals but Infrequently Used - A Nationwide Study
Authors: Mathilde Stærk, Kasper G Lauridsen, Kristian Krogh, Hans Kirkegaard, Bo Løfgren
Journal: Circulation (2017)

Introduction: Use of automated external defibrillators (AEDs) increase survival after out-of-hospital cardiac arrest but have not been shown to increase survival following in-hospital cardiac arres...
SAT0529 Short-term efficacy and safety of biosimilar rituximab in patients with systemic vasculitides
Authors: I. Smitienko, P. Novikov, S. Moiseev, A. Zykova, T. Shevtsova
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Objectives</h3> To study efficacy and safety of biosimilar (intended copy) rituximab (Acellbia, BIOCAD) in patients with systemic vasculitides. <h3>Methods</h3> We enrolled in our case series all consecutive patients with systemic vasculitides diagnosed according to CHCC2012 and ACR criteria (if applicable) who were treated with biosimilar rituximab since 2015. Activity of vasculitis was evaluated using BVAS3. CD19+ B-cells count was measured by standard method. Patients received intravenous rituximab at a 500 mg dose (four weekly infusions for remission induction or two weekly every 6 months infusions for maintenance treatment). <h3>Results</h3> In total, 45 patients were treated with biosimilar rituximab (29 GPA, 12 MPA, 1 EGPA, 2 cryoglobulemic vasculitis, 1 rheumatoid vasculitis). In 12 patients (7 GPA, 3 MPA, 1 CryoVas, 1 RheumVas), rituximab was administered for induction of remission due to high activity and relapsing course of vasculitis and low efficacy of previous treatment. 33 patients (22 GPA, 9 MPA, 1 EGPA, 1 CryoVas) received rituximab for maintenance of remission. Median duration of follow-up was 12 months.<sup>6–26</sup> At 1 and 3 months, all patients achieved B-cell depletion. At 6 months, B-cell repopulation was shown in 9 patients (20%). Remission induction therapy with rituximab resulted in decrease of median BVAS from 16 10–24 to 1 (0–4) at 3 months and to 0 (0–2) at 6 months. At 3 and 6 months, median prednisone dose was tapered from 50 mg 35–80 to 25 mg 15–40 and 10 mg, 5–20 respectively. In patients who received rituximab for maintenance treatment, median BVAS showed no disease activity (0–1) both at baseline and at 3 or 6 months. At baseline and at 3 months median doses of prednisolone were 5 mg (0–7.5) and 5 mg (0–5). At 6 months, it was reduced to 2.5 mg (0–5). Biosimilar rituximab had acceptable safety profile. Adverse events included mild infusion reaction,<sup>2</sup> urinary<sup>3</sup> and bronchopulmonary<sup>5</sup> infections which required intravenous antibiotics (median 4 months after infusions), hypogammaglobulinemia<sup>2</sup> that persisted for at least 12 months and 1 case of late-onset neutropenia in 8 months. <h3>Conclusions</h3> Biosimilar rituximab showed high efficacy and acceptable safety in patients with systemic vasculitides. <h3>Disclosure of Interest</h3> None declared
Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 As a Therapeutic Target for Restoring MHC Expression in Diffuse Large B-Cell Lymphoma
Authors: Daisuke Ennishi, Katsuyoshi Takata, Wendy Béguelin, Gerben Duns, Anja Mottok, Pedro Farinha, Ali Bashashati, David Scott, Merrill Boyle, Barbara Meissner, Susana Ben-Neriah, Bruce W Woolcock, Adele Telenius, Daniel Lai, Matthew R Teater, Robert Kridel, Kerry J Savage, Laurie H Sehn, Ryan D. Morin, Marco A. Marra, Sohrab P Shah, Joseph M. Connors, Randy D. Gascoyne, David W. Scott, Ari M Melnick, Christian Steidl
Journal: Blood (2018)
Perineuronal net formation during the critical period for neuronal maturation in the hypothalamic arcuate nucleus
Authors: Zaman Mirzadeh, Kimberly M. Alonge, Elaine Cabrales, Vicente Herranz-Pérez, Jarrad M. Scarlett, Jenny M. Brown, Rim Hassouna, Miles E. Matsen, Hong T. Nguyen, Jose Manuel Garcia-Verdugo, Lori M. Zeltser, Michael W. Schwartz
Journal: Nature Metabolism (2019)
AB1345 Evaluation of macrophage activation syndrome in hospitalised febrile patients with kikuchi-fujimoto disease based on the 2016 eular/acr/printo classification criteria
Authors: S.S. Ahn, H.J. Kim, H.W. Kim, S.M. Jung, S.-W. Lee, M.-C. Park, Y.-B. Park, J.J. Song
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> The incidence and the risk of MAS in Kikuchi-Fujimoto disease (KFD) have been poorly understood, probably because of the rarity of the disease. <h3>Objectives</h3> To evaluate the 2016 classification criteria for MAS in hospitalised febrile patients with KFD and compare the clinical features of MAS in KFD with those of systemic lupus erythematosus (SLE) and adult-onset Still's disease (AOSD). <h3>Methods</h3> The records of febrile patients with KFD, hospitalised between <sup>November 2005</sup> and April 2017, were reviewed. Patients were evaluated for MAS using the 2016 classification criteria. Clinical and laboratory features between patients with KFD with and without MAS, as well as those of patients with MAS in KFD, AOSD, and SLE were compared. <h3>Results</h3> Among 78 patients hospitalised with KFD, 24 had MAS during admission. Patients with MAS had longer hospital stays than patients without MAS and only patients with MAS required intensive unit care and experienced in-hospital mortality. Patients with MAS had higher C-reactive protein, aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, and ferritin levels and lower lymphocyte count, platelet count, and total protein and albumin levels. MAS patients with KFD, AOSD, and SLE exhibited different clinical characteristics according to the underlying disease; however, MAS patients with KFD required less intensive immunosuppressive treatment than those with AOSD and SLE. Comparison of HScore (A) and the probability of having hemophagocytic syndrome (B) in KFD patients with MAS and without MAS HScore, hemophagocytic syndrome score; KFD, Kikuchi-Fujimoto disease; MAS, macrophage activation syndrome. <h3>Conclusions</h3> The 2016 classification criteria were useful in identifying KFD patients with poor clinical outcome. Although treatment for patients with MAS in KFD, AOSD, and SLE differed according to the underlying disease, the 2016 classification criteria for MAS might aid in stratifying high-risk patients and provide guidance for treatment. <h3>References</h3> [1] International journal of dermatology. 2016;55(10):1069–75. [2] Ann Rheum Dis. 2016;75(3):481–9. <h3>Acknowledgements</h3> None. <h3>Disclosure of Interest</h3> None declared
RANKL/OPG expression ratio in prostate cancer cell lines with varying bone metastatic potential
Authors: Radhika Sharma, Wilhelmina Duivenvoorden, Gurmit Singh
Journal: Cancer Research (2008)

4087  Metastasis to bone can lead to extreme pain, deregulation of calcium, fractures, immobility and ultimately death. Bone metastatic lesions from prostate cancer are recurrent in 10-20% of patients who have undergone surgery to remove tumors. Current treatments for bone metastases are only palliative and include bisphosphonates and radiotherapy, but no effective curative treatment exists. Recently, the cytokine triad involved in regulating bone remodeling, osteoprotegerin (OPG), Receptor Activator of NF-κB ligand (RANKL) and Receptor Activator of NF-κB (RANK), has been examined as a possible therapeutic target in preventing bone metastasis from primary tumors. RANKL acts as an activator of osteoclastogenesis and osteoclast survival by binding to its cognate receptor RANK. This interaction has been identified as a causal factor for the osteolytic phenotype seen in various bone diseases. OPG is a decoy receptor for the interaction of RANK and RANKL, and inhibits bone resorption.  Recently, it has been suggested that the pattern of lesions identified in prostate cancer bone metastasis varies depending on the tumor microenvironment and is directly dependent on the RANKL/OPG ratio. Although evidence does imply the role of the cytokine triad OPG/RANKL/RANK in prostate cancer bone metastases, little is known about the changes that are elicited at the primary tumor site and the bone metastatic site. Here we investigated the changes in the RANKL/OPG ratio in prostate cancer cell lines with varying bone metastatic potential. We used the following human prostate cancer cell lines: CL-1, LNCaP, PC-3, DU-145, MDA-PCa2b, and 22Rv1. Western blotting analysis, ELISA, semi-quantitative PCR and real-time PCR measurements were used to quantify the ratio of these two cytokines between the cell lines. OPG gene expression was found to be 2- and 3-fold higher in CL-1 cells compared to PC-3 and LNCaP cells, respectively, while RANKL gene expression was 3- and 2-fold higher in PC-3 and LNCaP cells, respectively, compared to CL-1 cells. These results suggest that the RANKL/OPG ratio was lower in CL-1 cells and higher in PC-3 and LNCaP cells. Hence, the diversity of the prostate cancer phenotype in vitro suggests a potential role for the OPG/RANKL/RANK triad in mediating the type of bone metastatic lesions (osteoblastic vs. osteolytic).  Financial support is provided by the Prostate Cancer Research Foundation of Canada
AB0288 Levels of metalloproteinase-3 (MMP-3) correlate better with clinical disease activity index (CDAI) and simplified disease activity index (SDAI) than standard disease assessment score (DAS-28)
Authors: O. Vega, Y. Calvo, Z. Torres, R. Gamboa, S. Flores
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> The MMP-3 is a matrixin calcium-dependent zinc-containing; the major expressed in rheumatoid synovial tissue; with essential role in the degradation of both aggrecan and collagen fibrils. <h3>Objectives</h3> The aim was to evaluate the correlation of MMP3 levels with assessment scores of RA activity. <h3>Methods</h3> 109 patients with RA as per the 2010 ACR/EULAR criteria were included in the prospective Study ALTRA. Patients were divided into groups of early arthritis active, established arthritis active, and remission with conventional remissive or biological remissive. The levels of MMP3 and activity scores: DAS28-ERS, DAS28-CPR, SDAI and SDAI were on the basis of predefined cut-offs. The correlation was determined with the Pearson Test for parametric variables and the Spearman Test for non-parametric variables. <h3>Results</h3> The levels of MMP3 in patients with early RA Vs established were 63.2 and 39.9 U/ml, p&lt;0.021 respectively. MMP3 levels of patients with activity measured by DAS28-ESR were 62.9 in the active and 35.2 U/ml in remission, p&lt;0.000. The correlation between serum levels of MMP3 and DAS28-ERS was 0.21 (p&lt;0.25), with DAS28-CRP 0.27 (p&lt;0.004); CDAI 0.26 (p&lt;0.06) and with SDAI 0.35 (p&lt;0.002). <h3>Conclusions</h3> Elevated MMP3 levels indicate state of disease activity; besides the addition in the expression of the collagen damage. This finding may help in making decisions in clinical practice. <h3>References</h3> [1] Ohrndorf S, Fischer IU, Kellner H, Strunk J, Hartung W, Reiche B, et al. Reliability of the novel 7-joint ultrasound score: results from an inter- and intraobserver study performed by rheumatologists. Arthritis Care Res (Hoboken)2012;64(8):1238–43. [2] Houseman M, Potter C, Marshall N, Lakey R, Cawston T, Griffiths I, et al. Baseline serum MMP-3 levels in patients with Rheumatoid Arthritis are still independently predictive of radiographic progression in a longitudinal observational cohort at 8 years follow up. Arthritis Res Ther2012;14(1):R30. [3] Moller I, Janta I, Backhaus M, Ohrndorf S, Bong DA, Martinoli C, et al. The 2017 EULAR standardised procedures for ultrasound imaging in rheumatology. Ann Rheum Dis. 2017;76(12):1974–9. [4] Siddiqui IJ, Luz J, Borg-Stein J, O'Connor K, Bockbrader M, Rainey H, et al. The Current State of Musculoskeletal Ultrasound Education in Physical Medicine and Rehabilitation Residency Programs. PM R. 2016;8(7):660–6. [5] Willemze A, Toes RE, Huizinga TW, Trouw LA. New biomarkers in rheumatoid arthritis. Neth J Med. 2012;70(9):392–9. <h3>Acknowledgements</h3> Lic. Marcela Tafur <h3>Disclosure of Interest</h3> None declared
AB0733 Association of haematological parameters with disease manifestations, activity, and severity in patients with systemic sclerosis
Authors: M.E. Yayla, U. İlgen, I.E. Okatan, E. Uslu Yurteri, M. Torğutalp, A.B. Keleşoğlu Dinçer, E.G. Aydemir Gülöksüz, S. Sezer, T.M. Turgay, G. Kınıklı, A. Ateş
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), eosinophil-to-lymphocyte ratio (ELR), basophil-to-lymphocyte ratio (BLR), and mean platelet volume (MPV) may potentially reflect inflammatory status in systemic autoimmune diseases. <h3>Objectives</h3> The aim of this study is to investigate the association of NLR, MLR, ELR, BLR and MPV with disease manifestations, activity and severity in patients with systemic sclerosis (SSc). <h3>Methods</h3> 59 patients with SSc and 50 healthy controls were included in the study. All patients were diagnosed according to the 2013 ACR/EULAR systemic sclerosis classification criteria. Adult patients with SSc and healthy controls were compared in terms of NLR, MLR, ELR, BLR and MPV. <h3>Results</h3> SSc and control groups had similar ages and genders. Lymphocyte number was lower in SSc group compared to controls (p&lt;0.001). SSc group also have higher NLR and MLR (table 1). There were no significant differences in ELR and BLR ratios between SSc patients and controls. Patients with active disease (2.9 [IQR 2.13], p=0.042), pulmonary hypertension (PHT), digital ulcers, and tendon friction rubs (TFR) had higher NLRs (table 2). MLR was also higher in dcSSc patients (0.28 [IQR 0.73]) compared to lcSSc (0.2 [IQR 0.48] (p=0.045), and there were also significant associations with disease manifestations like digital ulcers, tendon friction rubs (table 2). MLR was positively correlated with mRSS (rho=0.35 p=0.009), Valentini (rho=0.453 p=0.001) and Medsger (rho=0.283 p=0.036) scores. According to capillaroscopy images, patients with late stage findings had higher MLRs compared to patients with normal findings (0.27 [IQR 0.3] vs 0.15 [IQR 0.04], p&lt;0.001). Patients with digital ulcers (p=0.02) and arthritis (p=0.013) had higher ELRs and patients with tendon friction rubs has higher ELRs (p=0.014) and BLRs (0.036) compared to those without. There was no significant relation between MPV and disease manifestations (table 2). There were no relationships between dysmotility and haematological parameters. MPV, NLR and MLR are given as medians (interquartile ranges).+and – denote presence and absence, respectively. <h3>Conclusions</h3> According to our study, as NLR and MLR are simple, practical, cost-effective markers, they can used for evaluation of disease manifestations, activity and severity in SSc. <h3>Disclosure of Interest</h3> None declared
THU0681 Establishing the bath ankylosing spondylitis metrology index (BASMI) normative values in a malaysian population: the importance of sex and age factors
Authors: A.F. Nurul Aain, I.S. Lau, S.C. Gun, S. Wahinuddin, P.S. Ong, H. Heselynn, B.E. Tan, H.C. Chong, A. Hilmi, M. Asmah, M.I. Asmahan, Y.L. Loh, A.L. Lim, H. Noor Shahrazat, C.L. Teh, G.R. Ling, E.Y.Y. Chong, A.H. Ruhaila, A.M. Suhaida, R. Shamala, R. Azmillah, M.Z. Mollyza, S. Salsabil, L.K. Tan, M. Shahnaz, C.L. Too
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Ankylosing spondylitis (AS) is a chronic spinal inflammatory disorder which leads to progressive fusion and deformity. The loss of spinal mobility is recognised as an important clinical sign. The BASMI, a composite index of spinal mobility is used internationally in clinical practice and research. However, the interpretation of BASMI has been impeded by the absence of normative values. <h3>Objectives</h3> We aimed to attain the normative values for BASMI in Malaysian healthy individuals. <h3>Methods</h3> BASMI data of 142 healthy individuals and 187 AS patients were analysed. Each BASMI component was assessed, using the 10-point scoring system, where zero is no mobility and 10 is very severe limitation. Measurements were performed by the rheumatologists and trained researchers following a designated protocol. Data were summarised and analysed according to sex and age groups. <h3>Results</h3> The total BASMI scores ranged from 0.2 to 4.2 and 0.6 to 9.6 in the healthy individuals and the AS cases, respectively. There was no significant difference for the BASMI median score between healthy men and women (men=1.2, women=1.6, p&gt;0.05). The estimated median score for healthy individuals aged 15–19 years was 1.2, increasing with age to 2.7 for healthy individuals aged ≥60 years. In AS cases, the estimated median score was 5.4 and 5.8 for men and women, respectively (p&gt;0.05). We observed significant increase of estimated median score between AS patients aged 15–19 years (BASMI score=2.0) and AS patients aged ≥60 years (BASMI score=6.4) (p&lt;0.05). <h3>Conclusions</h3> Our data suggest that it is uncommon for healthy individuals to score zero on the BASMI. The magnitude of increase in BASMI score is apparent with increasing age, but not sex in the healthy individuals. Establishment of normative values may aid baseline measurement and monitor change of spinal mobility in AS patients over time, as well as help assess the impact of clinical interventions. <h3>Disclosure of Interest</h3> None declared
SAT0658 Quantitative analysis of joint structure by hr-pqct in patients with rheumatoid arthritis: correlation between cartilage loss and bone deterioration
Authors: K. Chiba, N. Iwamoto, N. Oki, K. Watanabe, M. Osaki, A. Kawakami
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> HR-pQCT is a high-resolution CT dedicated to human extremities. It has been used for the study of rheumatoid arthritis (RA) in recent years, enabling quantitative analysis of bone erosion, bone microstructure, and joint space. <h3>Objectives</h3> The purpose of this study is to investigate a correlation between cartilage loss and bone deterioration (juxta-articular osteoporosis and erosion) in patients with RA by HR-pQCT. <h3>Methods</h3> Twenty patients with RA (70±8 years, 15 female, 5 male) participated in this study. The second and third MCP joints were scanned by second-generation HR-pQCT (XtremeCT II, Scanco Medical, Switzerland) at the voxel size of 61 µm. The following parameters were measured semiautomatically using dedicated software (TRI/3D-BON, Ratoc System Engineering, Tokyo) based on previous studies<sup>1–3</sup>. 1) Average joint space width (ave-JSW) of MCP joints, 2) bone microstructure of metacarpal head: volumetric bone mineral density (vBMD), trabecular thickness (Tb.Th), trabecular number (Tb.N), and structure model index (SMI), 3) total volume of erosions (ER-volume) on the metacarpal head. <h3>Results</h3> Ave-JSW of MCP joints was 1.47 (1.00–1.89) mm. vBMD of the metacarpal head was 131.4 (54.3–263.5) mg/cm<sup>3</sup>, Tb.Th was 213.1 (166–329.3) mm, Tb.N was 0.95 (0.69–1.50)/mm, and SMI was 1.68 (0.65–2.52). The total number of erosions was 31, and an average number of erosions on each metacarpal head was 0.9 (0–4). Total ER-volume on the metacarpal head was 1.96 (0–16.7) mm<sup>3</sup>. Ave-JSW had significant correlations with vBMD, SMI and ER-volume (R=0.37,–0,40, −0.42, p&lt;0.05). <h3>Conclusions</h3> Cartilage loss was correlated with juxta-articular osteoporosis and bone erosion in RA patients. Quantitative evaluation of total joint structure (joint space, bone microstructure, and erosion) by HR-pQCT would be useful for the pathophysiological research and drug development of RA. <h3>References</h3> [1] Burghardt AJ, et al. Ann Biomed Eng2013. [2] Yang H, et al. Int J Rheum Dis2017. [3] Chiba K, et al. Eular2017. <h3>Disclosure of Interest</h3> None declared
Outcomes Following Hematopoietic Stem Cell Transplantation in Patients Treated with Chemotherapy with or without Gemtuzumab Ozogamicin for Acute Myeloid Leukemia
Authors: Cécile Pautas, Emmanuel Raffoux, Juliette Lambert, Ollivier Legrand, Sylvain Chantepie, Lauris Gastaud, Jean-Pierre Marolleau, Xavier Thomas, Pascal Turlure, Rebecca Benner, Erik Vandendries, Karïn Gogat, Hervé Dombret, Sylvie Castaigne
Journal: Blood (2018)